[go: up one dir, main page]

WO2025049451A1 - Dosages pour détecter le cytomégalovirus (cmv) ou le virus d'epstein-bar (ebv) - Google Patents

Dosages pour détecter le cytomégalovirus (cmv) ou le virus d'epstein-bar (ebv) Download PDF

Info

Publication number
WO2025049451A1
WO2025049451A1 PCT/US2024/044002 US2024044002W WO2025049451A1 WO 2025049451 A1 WO2025049451 A1 WO 2025049451A1 US 2024044002 W US2024044002 W US 2024044002W WO 2025049451 A1 WO2025049451 A1 WO 2025049451A1
Authority
WO
WIPO (PCT)
Prior art keywords
ebv
cmv
seq
well
amplification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/044002
Other languages
English (en)
Inventor
Dan R. TOOLSIE
Shihai Huang
Frances Lennon
Xin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Molecular Inc
Original Assignee
Abbott Molecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Molecular Inc filed Critical Abbott Molecular Inc
Publication of WO2025049451A1 publication Critical patent/WO2025049451A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage

Definitions

  • CMV CYTOMEGALOVIRUS
  • EBV EPSTEIN-BAR VIRUS
  • CMV cytomegalovirus
  • EBV Epstein-Bar virus
  • Viral infections are a major cause of morbidity and mortality in a diversity of clinical settings including, for example, care of immunocompromised patients and postoperative care of solid organ transplant recipients.
  • Chronic immunosuppression required to maintain allograft function post-organ transplant predisposes transplant patients to viral infections. These may arise at each stage post-transplantation.
  • Certain infections, such as cytomegalovirus (CMV) or Epstein Barr virus (EBV) may occur within months after transplantation.
  • CMV infections may be prevented by prophylaxis therapy, and EVB infections may be managed by decreasing immunosuppression. Accordingly, methods, compositions, kits and systems for detecting nucleic acid sequences from CMV or EBV in samples including, for example, plasma, whole blood and urine samples are needed.
  • a set of oligonucleotides comprises at least one first amplification oligonucleotide, at least one second amplification oligonucleotide, and at least one probe oligonucleotide.
  • the probe oligonucleotide may comprise a detectable label (e.g., a fluorophore).
  • the set of oligonucleotides is for polymerase amplification and detection of CMV and/or EBV in a sample.
  • the reagents comprise a group of oligonucleotides comprising one or more sets of oligonucleotides.
  • the present invention provides dual-target PCR primer and probe sets for each of CMV or EBV nucleic acid sequences.
  • whole blood is prepared for CMV and/or EBV detection by a method comprising one or more of: instrument preparation comprising filling an integrated reaction unit with one or more of a lysis buffer and a wash buffer, an Internal Control, Proteinase K, 30pL +/- 20% silica microparticles, and 70pL +/- 20% elution buffer; pretreatment comprising addition of 300pL +/- 20% sample plus 400pL +/- 20% lysis buffer to a pretreatment well and incubation of the sample in the pretreatment well with Proteinase K and lysis solution at 50°C +/- 20%; lysis comprising transfer of the pretreated sample to a lysis well comprising 1300pL +/- 20% lysis buffer and microparticles incubated at 68°C +/- 20% with mixing by a magnetic plunger sheathed with a disposable plastic sheath during incubation; washing comprising transfer of the microparticles to a wash well comprising 1200pL +/- 20% lysis buffer
  • the present invention provides a method for detecting CMV, and/or EBV in a whole blood sample, comprising: a) incubation of the sample with Proteinase K in a pretreatment well at 50°C; b) transfer of the incubated sample of step a) to a lysis well comprising lysis buffer and magnetic microparticles followed by mixing and incubation at 68°C in the well; c) transfer of the magnetic microparticles of step b) to a first wash well comprising lysis buffer; d) transfer of the magnetic microparticles of step c) to a second wash well and washing the microparticles with a mixture of ethanol and water; e) capture of the magnetic microparticles of step d) with a plunger magnet and evaporation of the ethanol; f) transfer of the magnetic microparticles of step e) to an elution well comprising an elution buffer; g) elution of purified DNA from the magnetic microparticle
  • the one or more amplification primers comprise one or more of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 5. In some embodiments, the one or more amplification primers comprise one or more of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, and SEQ ID NO: 14. In some embodiments, the one or more probes comprise one or more of SEQ ID NO: 3 and SEQ ID NO: 6. In some embodiments, the one or more probes comprise one or more of SEQ ID NO: and SEQ ID NO: 15.
  • the present invention provides a system comprising: a) a pipettor; b) an integrated reaction unit (IRU) comprising one or more lanes comprising in linear order of sample transfer: 1) a pretreatment well comprising Proteinase K and lysis solution at 50°C and an internal control; 2) a lysis well comprising lysis buffer and silica magnetic microparticles at 68°C and a magnetic microparticle transfer plunger sheathed with a disposable plastic sheath; 3) a wash well comprising lysis buffer; 4) a first wash well comprising ethanol and water; 5) a second wash well comprising ethanol and water; 6) an elution well comprising an elution buffer at 72°C; and 7) a PCR reaction vessel comprising activator formulation, Mastermix and one or more CMV or EBV primer pairs and probes; c) a thermocycler: and d) a fluorescence detector.
  • IRU integrated reaction unit
  • the disclosure also provides methods for detecting CMV or EBV in a sample.
  • the sample may comprise a nasal swab or brush, saliva, mucus, blood, serum, plasma, urine or feces.
  • kits for detecting CMV or EBV in a sample comprising at least one set of oligonucleotides, any of the oligonucleotides as disclosed herein, reagents for amplifying and detecting nucleic acid sequences, and/or instructions for use.
  • Figures 1 A and IB show CMV and EBV sensitivity results with over 95% detection at 100 IU for Alinity m CMV and EBV in whole blood (WB).
  • Figures 2A and 2B show linearity results of CMV and EBV in WB. All genotypes were evaluated across multiple target levels: CMV : 80 - 2 x 10 8 lU/mL and EBV 80 - 4 x 10 8 lU/mL with 24 replicates at each target level.
  • Figures 3A and 3B show CMV and EBV in WB precision results. Each panel member was tested in multiple replicates twice each day for 5 days on 3 Alinity m systems by 3 operators using 3 AMP kits.
  • Figures 4A and 4B show CMV in WB clinical specimen quantitation vs. RealTime CMV.
  • 108 quantified fresh and frozen specimens from hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) patients and other immunocompromised patients were collected from 5 sites.
  • Top plot: N 108, slope: 1.05, Intercept: -0.14, r: 0.958.
  • Bottom plot: Mean bias 0.01 Log/mL.
  • Figure 5 shows concordance between Alinity m CMV in WB assays vs. RealTime CMV assays. 736 fresh and frozen samples from HSCT, SOT and other immunocompromised patients were collected at 5 sites.
  • Figure 7 shows concordance between Alinity m EBV in WB assays vs. RealTime EBV assays. 378 fresh and frozen samples from transplant and other immunocompromised patients were collected at 5 sites.
  • CMV cytomegalovirus
  • EBV Epstein-Bar virus
  • CMV cytomegalovirus
  • cytomegalovirus a double-stranded Herpesviridae DNA virus
  • CMV infection among renal transplant recipients is caused by drug-induced T-cell immunosuppression leading to activation and replication of CMV after surgery.
  • CMV infection may comprise viral penetration of diverse tissues and organs including the liver, gastrointestinal organs, the renal graft, lungs, retina and bone marrow. Accordingly, CMV monitoring and prevention strategies are in frequent use in the post-operative care of transplant recipients.
  • Preventive therapy reduces reactivation of latent CMV infection and acquisition of acute infection in CMV-negative recipients of seropositive grafts.
  • CMV disease may still occur despite preventive therapies, especially when infections are not dosed adequately.
  • CMV disease also occurs following discontinuation of preventive therapy. Post-transplant patients undergo PCR testing for 3 months or longer after surgery to measure viral load to assess CMV risk and severity, guide therapeutic interventions, rapidly diagnose CMV infection, and monitor the effectiveness of therapy detect antiviral resistance.
  • Epstein-Barr virus also known as human herpesvirus 4
  • EBV Epstein-Barr virus
  • PTLD Post-transplant lymphoproliferative disease
  • NPC nasopharyngeal cancer
  • EBV infection Diagnosis of EBV infection is immunocompetent individuals is done either by clinical diagnosis or by antibody testing in patient exhibiting characteristic signs and symptoms of infectious mononucleosis or other illnesses caused by EBV infection.
  • rising EBV viral titers raise the suspicion of EBV-related PTLD with confirmation by biopsy.
  • quantitative monitoring of EBV viral load is required in support of clinical management to accurately distinguish health low-level carriers from high-level infected patients.
  • high risk individuals including transplant recipients benefit from regular screening to track possible disease progression.
  • Traditional serological methods for EBV detection are constrained in immunosuppressed patients due to the high probability of varied serology profiles, consequently real-time PCR is preferred for viral load measurement.
  • EBV related illness varies based on immunocompetence as well as type of EBV related illness.
  • therapeutic strategies include a reduction in immunosuppression for 2-4 weeks, monoclonal antibody therapy, chemotherapy, EBV- specific cytotoxic T-cell therapy and steroids.
  • the terms “comprise(s)”, “include(s)”, “having”, “has”, “can”, “contain(s)”, and variants thereof are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures.
  • the singular forms “a”, “and” and “the” include plural references unless the context clearly dictates otherwise.
  • the present disclosure also contemplates other embodiments “comprising,” “consisting of’ and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.
  • each intervening number there between with the same degree of precision is explicitly contemplated.
  • the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.
  • first and second are used in this disclosure in their relative sense only. It will be understood that, unless otherwise noted, those terms are used merely as a matter of convenience in the description of one or more of the embodiments. The terms “first” and “second” are only used to distinguish one element from another element, and the scope of the rights of the disclosed technology should not be limited by these terms. For example, a first element may be designated as a second element, and similarly the second element may be designated as the first element.
  • oligonucleotide refers to a short nucleic acid sequence comprising from about 2 to about 100 nucleotides (e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, or 100 nucleotides, or a range defined by any of the foregoing values).
  • nucleic acid and polynucleotide refer to a polymeric form of nucleotides of any length, either ribonucleotides (RNA) or deoxyribonucleotides (DNA).
  • RNA and DNA refer to the primary structure of the molecule, and thus include double- and single- stranded DNA, and double- and single-stranded RNA.
  • the terms include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs and modified polynucleotides such as, for example, methylated and/or capped polynucleotides.
  • Nucleic acids are typically linked via phosphate bonds to form nucleic acid sequences or polynucleotides, though many other linkages are known in the art (e.g., phosphorothioates, boranophosphates, and the like).
  • Oligonucleotides can be single- stranded or double-stranded or can contain portions of both double-stranded and single-stranded sequences.
  • the oligonucleotide can be DNA, both genomic and complimentary DNA (cDNA), RNA, or a hybrid, where the nucleic acid can contain combinations of deoxyribo- and ribonucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine and isoguanine.
  • Oligonucleotides can be obtained by chemical synthesis methods or by recombinant methods.
  • percent sequence identity refers to the percentage of nucleotides or nucleotide analogs in a nucleic acid sequence, or amino acids in an amino acid sequence, that is identical with the corresponding nucleotides or amino acids in a reference sequence after aligning the two sequences and introducing gaps, if necessary, to achieve the maximum percent identity.
  • nucleic acid according to the technology is longer than a reference sequence, additional nucleotides in the nucleic acid, that do not align with the reference sequence, are not taken into account for determining sequence identity.
  • Methods and computer programs for alignment are well known in the art, including BLAST, Align 2, and FASTA.
  • the methods, steps, compositions, and kits described herein are used for whole blood sample pretreatment before CMV and/or EBV amplification, detection, identification, and quantification.
  • a solution comprising proteinase K (PK) and a lysis buffer comprising, for example, guanidine isothiocyanate (GITC)
  • GITC guanidine isothiocyanate
  • GITC inactivates PK by its denaturation, thereby resulting in under-quantification of the viral load in the whole blood sample. It was further discovered that a low concentration of GITC (including no GITC) allows full activity of PK in releasing cellular components from the whole blood samples, thereby resulting in undesirable formation of whole blood and magnetic microparticle aggregates during the lysis step i.e., “clumping”. In experiments conducted during the course of development of the present invention, it was discovered that a specific amount of GITC combined with PK resolves the pretreatment problems of both 1) inaccurate quantification of the viral load from whole blood and 2) clumping during the lysis step.
  • the concentration of GITC is 1.74 M to 2.80 M. In some embodiments, the concentration of GITC is 2.42 M to 2.69 M. In some embodiments, the concentration of GITC is 2.54 M. In some embodiments, the amount of PK is 0.4 U to 1.2 U per reaction. In some embodiments, the amount of PK is 0.6 U to 0.9 U per reaction. In some embodiments, the amount of PK is 0.76 U per reaction.
  • the pretreatment temperature is 40 °C to 65 °C. In some embodiments, the pretreatment temperature is 48°C to 52 °C. In some embodiments, the pretreatment temperature is 50 °C. In some embodiments, the lysis temperature is 50 °C to 72 °C. In some embodiments, the lysis temperature is 65 °C to 70 °C. In some embodiments, the lysis temperature is 68 °C.
  • the oligonucleotides described herein may be used for nucleic acid amplification (e. ., primers) or as probes for nucleic acid hybridization and detection.
  • primer refers to an oligonucleotide which is capable of acting as a point of initiation of synthesis of an extension product that is a complementary strand of nucleic acid (all types of DNA or RNA) when placed under suitable amplification conditions (e.g., buffer, salt, temperature and pH) in the presence of nucleotides and an agent for nucleic acid polymerization (e.g., a DNA-dependent or RNA-dependent polymerase).
  • suitable amplification conditions e.g., buffer, salt, temperature and pH
  • the amplification oligonucleotides of the present disclosure can be of any suitable size, and desirably comprise, consist essentially of, or consist of about 15 to 50 nucleotides, preferably about 20 to 40 nucleotides.
  • the oligonucleotides of the present disclosure can contain additional nucleotides in addition to those described herein.
  • the amplification oligonucleotides can include, for example, a nicking enzyme site and a stabilizing region upstream (see, e.g., U.S. Patent Nos 9,689,031; 9,617,586; 9,562,264; and 9,562,263, each of which is incorporated herein by reference in its entirety).
  • probe refers to an oligonucleotide that can selectively hybridize to at least a portion of a target sequence (e.g., a portion of a target sequence that has been amplified) under appropriate hybridization conditions.
  • a probe sequence is identified as being either “complementary” (e.g., complementary to the coding or sense strand (+)), or “reverse complementary” (e.g., complementary to the anti-sense strand (-)).
  • the probes of the present disclosure can be of any suitable size, and desirably comprise, consist essentially of, or consist of about 10-50 nucleotides, preferably about 12-35 nucleotides.
  • set refers to two or more oligonucleotides which together are capable of priming the amplification of a target sequence or target nucleic acid of interest (e.g., a target sequence within CMV or EBV) and/or at least one probe which can detect the target sequence or target nucleic acid.
  • target sequence or target nucleic acid of interest e.g., a target sequence within CMV or EBV
  • the term “set” refers to a pair of oligonucleotides including a first oligonucleotide that hybridizes with the 5 ’-end of the target sequence or target nucleic acid to be amplified and a second oligonucleotide that hybridizes with the complement of the target sequence or target nucleic acid to be amplified.
  • the set of oligonucleotides described herein may be used to amplify and detect one or more target CMV or EBV sequences in a sample.
  • target sequence and “target nucleic acid” are used interchangeably herein and refer to a specific nucleic acid sequence, the presence or absence of which is to be detected by the disclosed method.
  • a target sequence preferably includes a nucleic acid sequence to which one or more oligonucleotides will hybridize and from which amplification will initiate.
  • the target sequence can also include a probe-hybridizing region with which a probe may form a stable hybrid under appropriate amplification conditions.
  • a target sequence may be singlestranded or double-stranded.
  • the target CMV or EBV sequence may be within any portion of the CMV or EBV genome.
  • the set comprises a first amplification oligonucleotide, a second amplification oligonucleotide, and a probe oligonucleotide.
  • any of the oligonucleotides described herein may be modified in any suitable manner so as to stabilize or enhance the binding affinity of the oligonucleotide for its target.
  • an oligonucleotide sequence as described herein may comprise one or more modified oligonucleotide.
  • any of the sequences listed which include internal spacers or modifications may be used without the modifications or spacers.
  • any of the oligonucleotides described herein may include, for example, spacers, blocking groups, and modified nucleotides.
  • Modified nucleotides are nucleotides or nucleotide triphosphates that differ in composition and/or structure from natural nucleotides and nucleotide triphosphates. Modifications include those naturally occurring that result from modification by enzymes that modify nucleotides, such as methyltransferases. Modified nucleotides also include synthetic or non-naturally occurring nucleotides. For example, modified nucleotides include those with 2' modifications, such as 2'-O-methyl and 2'-fluoro.
  • Modified nucleotides or nucleotide triphosphates used herein may, for example, be modified in such a way that, when the modifications are present on one strand of a double-stranded nucleic acid where there is a restriction endonuclease recognition site, the modified nucleotide or nucleotide triphosphates protect the modified strand against cleavage by restriction enzymes.
  • Blocking groups or polymerase-arresting molecules are chemical moieties that inhibit target sequence-independent nucleic acid polymerization by the polymerase.
  • the blocking group may render the oligonucleotide capable of binding a target nucleic acid molecule, but incapable of supporting template extension utilizing the detectable oligonucleotide probe as a target.
  • the presence of one or more moieties that do not allow polymerase progression likely causes polymerase arrest in non-nucleic acid backbone additions to the oligonucleotide or through stalling of a replicative polymerase. Oligonucleotides with these moieties may prevent or reduce illegitimate amplification of the probe during the course of the amplification reaction.
  • blocking groups include, for example, alkyl groups, non-nucleotide linkers, phosphorothioate, alkane-diol residues, peptide nucleic acid, and nucleotide derivatives lacking a 3 '-OH, including, for example, cordycepin, spacer moieties, damaged DNA bases and the like.
  • spacers include, for example, C3 spacers. Spacers may be used, for example, within the oligonucleotide, and also, for example, at the ends to attach other groups, such as, for example, labels.
  • any of the oligonucleotide sequences described herein may comprise, consist essentially of, or consist of a complement of any of the sequences disclosed herein.
  • the terms “complement” or “complementary sequence” as used herein refer to a nucleic acid sequence that forms a stable duplex with an oligonucleotide described herein via Watson-Crick base pairing rules, and typically shares about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% greater identity with the disclosed oligonucleotide.
  • Nucleic acid sequence identity can be determined using any suitable mathematical algorithm or computer software known in the art, such as, for example, CLUSTAL-W, T-Coffee, and ALIGN (for alignment of nucleic acid and amino acid sequences), BLAST programs (e.g., BLAST 2.1, BL2SEQ, and later versions thereof) and FASTA programs (e.g., FASTA3 '. FASTM, and SSEARCH) (for sequence alignment and sequence similarity searches). Sequence alignment algorithms also are disclosed in, for example, Altschul et al., J. Molecular Biol., 215(3): 403-410 (1990); Beigert et al., Proc. Natl. Acad. Sci.
  • oligonucleotides described herein may be prepared using any suitable method, a variety of which are known in the art (see, for example, Sambrook et al., Molecular Cloning. A Laboratory Manual, 1989, 2. Supp. Ed., Cold Spring Harbour Laboratory Press: New York, N.Y.; M. A. Innis (Ed.), PCR Protocols. A Guide to Methods and Applications, Academic Press: New York, N.Y. (1990); P. Tijssen, Hybridization with Nucleic Acid Probes - Laboratory Techniques in Biochemistry and Molecular Biology (Parts I and II), Elsevier Science (1993); M. A. Innis (Ed.), PCR Strategies, Academic Press: New York, N.Y. (1995); and F.
  • Oligonucleotide pairs also can be designed using a variety of tools, such as the Primer-BLAST tool provided by the National Center of Biotechnology Information (NCBI).
  • Oligonucleotide synthesis may be performed on oligo synthesizers such as those commercially available from Perkin Elmer/ Applied Biosystems, Inc. (Foster City, CA), DuPont (Wilmington, DE), or Milligen (Bedford, MA).
  • oligonucleotides can be custom made and obtained from a variety of commercial sources well-known in the art, including, for example, the Midland Certified Reagent Company (Midland, TX), Eurofins Scientific (Louisville, KY), BioSearch Technologies, Inc. (Novato, CA), and the like.
  • Oligonucleotides may be purified using any suitable method known in the art, such as, for example, native acrylamide gel electrophoresis, anion-exchange HPLC (see, e.g., Pearson et al., J. Chrom., 255: 137-149 (1983), incorporated herein by reference), and reverse phase HPLC (see, e.g., McFarland et al., Nucleic Acids Res., 7: 1067-1080 (1979), incorporated herein by reference).
  • suitable method known in the art such as, for example, native acrylamide gel electrophoresis, anion-exchange HPLC (see, e.g., Pearson et al., J. Chrom., 255: 137-149 (1983), incorporated herein by reference), and reverse phase HPLC (see, e.g., McFarland et al., Nucleic Acids Res., 7: 1067-1080 (1979), incorporated herein by reference).
  • the sequence of the oligonucleotides can be verified using any suitable sequencing method known in the art, including, but not limited to, chemical degradation (see, e.g., Maxam et al., Methods of Enzymology, 65: 499-560 (1980), incorporated herein by reference), matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (see, e.g., Pieles et al., Nucleic Acids Res., 21: 3191-3196 (1993), incorporated herein by reference), mass spectrometry following a combination of alkaline phosphatase and exonuclease digestions (Wu et al., Anal. Biochem., 290: 347-352 (2001), incorporated herein by reference), and the like.
  • Detectable Label see, e.g., Maxam et al., Methods of Enzymology, 65: 499-560 (1980), incorporated here
  • any one or more of the oligonucleotide sequences described herein may comprise a detectable label, such that the amplification oligonucleotide(s) and/or the probe oligonucleotide can be measured.
  • each of the probe oligonucleotide sequences described herein comprise a detectable label.
  • detectable label refers to a moiety or compound that generates a signal which can be measured and whose intensity is related to (e.g., proportional to) the amount of entity bound thereto.
  • any suitable detectable label that can be conjugated or linked to an oligonucleotide in order to detect binding of the oligonucleotide to a target sequence can be used, many of which are known in the art.
  • the detectable label may be detected indirectly.
  • Indirectly detectable labels are typically specific binding members used in conjunction with a “conjugate” that is attached or coupled to a directly detectable label. Coupling chemistries for synthesizing such conjugates are well-known in the art and are designed such that the specific binding property of the specific binding member and the detectable property of the label remain intact.
  • binding member and “conjugate” refer to the two members of a binding pair, e.g., two different molecules, where the specific binding member binds specifically to the polynucleotide of the present disclosure, and the “conjugate” specifically binds to the specific binding member. Binding between the two members of the pair is typically chemical or physical in nature. Examples of such binding pairs include, but are not limited to, antigens and antibodies, avidin/streptavidin and biotin, haptens and antibodies specific for haptens, complementary nucleotide sequences, enzyme cofactors/substrates and enzymes, and the like.
  • Each of the probe oligonucleotide sequences desirably comprises a detectable label.
  • Each of the probes may be labeled with the same detectable label or different detectable labels.
  • the detectable label may be directly detected.
  • directly detectable labels include, for example, radioisotopes, fluorophores, chemiluminophores, enzymes, colloidal particles, fluorescent microparticles, intercalating dyes (e.g., SYBR Green or ethidium bromide), and the like.
  • the detectable label may be a fluorophore, such as a fluorescein-family dye, polyhalofluorescein-family dye, hexachlorofluorescein-family dye, coumarin-family dye, rhodamine-family dye, cyanine- family dye, oxazine-family dye, thiazin-family dye, squaraine-family dye, chelated lanthanide-family dye, azo-family dye, triphenylmethane-family dye, or a BODIPY®-family dye.
  • a fluorescein-family dye such as a fluorescein-family dye, polyhalofluorescein-family dye, hexachlorofluorescein-family dye, coumarin-family dye, rhodamine-family dye, cyanine- family dye, oxazine-family dye, thiazin-family dye, squaraine-family dye, chelated lanthanide-family dye, azo
  • fluorophores examples include, but are not limited to, FAMTM, CAL-FLUOR®, QUASAR®, HEXTM, JOETM, NEDTM, PET®, ROXTM, TAMRATM, TETTM, TEXAS RED®, and VIC®.
  • FAMTM FAMTM
  • CAL-FLUOR® QUASAR®
  • HEXTM JOETM
  • NEDTM NEDTM
  • PET® ROXTM
  • TAMRATM TAMRATM
  • TETTM TEXAS RED®
  • VIC® VIC®
  • Methods for labeling oligonucleotides, such as probes are well-known in the art and described in, e.g., L. J. Kricka, Ann. Clin.
  • any one or more of the oligonucleotides described herein may also comprise a quencher moiety.
  • a detectable label e.g., a fluorophore
  • quencher moiety prevents detection of a signal (e.g., fluorescence) from the detectable label.
  • a signal e.g., fluorescence
  • the quencher may be selected from any suitable quencher known in the art, such as, for example, BLACK HOLE QUENCHER® 1 (BHQ-1®), BLACK HOLE QUENCHER® 2 (BHQ-2®), BLACK HOLE QUENCHER® 3 (BHQ-3®), IOWA BLACK® FQ, and IOWA BLACK® RQ.
  • the oligonucleotide probe may comprise a FAM fluorophore, CAL-FLUOR®, or QUASAR fluorophore and a BHQ-1 or BHQ-2 quencher.
  • the present disclosure provides a method for detecting CMV or EBV in a sample.
  • the method comprises: contacting a sample with the set of oligonucleotides disclosed herein and reagents for amplification; amplifying one or more target CMV or EBV nucleic acid sequences present in the sample; hybridizing one or more of the oligonucleotide probes to one or more amplified target CMV or EBV nucleic acid sequences; and detecting hybridization of the one or more probe oligonucleotide sequences to the one or more amplified CMV or EBV target nucleic acid sequences by measuring a signal from the detectable labels.
  • Descriptions of the oligonucleotides set forth herein with respect to the aforementioned set of oligonucleotides also are applicable to the disclosed method.
  • the sample can be any suitable sample obtained from any suitable subject, typically a mammal (e.g., dogs, cats, rabbits, mice, rats, goats, sheep, cows, pigs, horses, non-human primates, or humans).
  • the subject is a human.
  • the sample may be obtained from any suitable biological source, such as, a nasal swab or brush, or a physiological fluid including, but not limited to, whole blood, serum, plasma, interstitial fluid, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, mucous, synovial fluid, peritoneal fluid, vaginal fluid, menses, amniotic fluid, semen, feces, and the like.
  • the present invention provides compositions, methods, systems and kits for isolation, detection, identification and/or quantification of CMV and EBV in whole blood.
  • experiments conducted in the course of development of the present invention it was discovered that the addition of an aliquot of whole blood to a solution comprising Proteinase K and incubation at 50°C prior to transfer to a cell lysis well containing lysis buffer and microparticles surprisingly supports quantitative analysis of CMV and EBV viral load in whole blood using real-time PCR.
  • compositions, methods, systems and kits of the present invention configured for quantitative analysis of CMV and EBV viral load in whole blood samples fulfill a long felt unmet need essential to determination of the requirement, selection and dosing of immunosuppressive and antiviral medications in the care of immunocompromised patients and organ transplant recipients after surgery.
  • the sample can be obtained from the subject using routine techniques known to those skilled in the art, and the sample may be used directly as obtained from the biological source or following a pretreatment to modify the character of the sample.
  • a pretreatment may include, for example, preparing plasma from blood, diluting viscous fluids, filtration, precipitation, dilution, distillation, mixing, concentration, inactivation of interfering components, the addition of reagents, lysing, and the like.
  • the sample may be contacted with the set of oligonucleotides comprising amplification oligonucleotides and probes as described herein to form a reaction mixture.
  • the reaction mixture is then placed under amplification conditions.
  • amplification conditions refers to conditions that promote annealing and/or extension of the amplification oligonucleotides. Amplification conditions encompass all reaction conditions including, but not limited to, temperature and/or temperature cycling, buffer, salt, ionic strength, pH, and the like.
  • Amplifying a CMV or EBV nucleic acid sequence in the sample can be performed using any suitable nucleic acid sequence amplification method known in the art.
  • the amplification includes, but is not limited to, polymerase chain reaction (PCR), reverse-transcriptase PCR (RT-PCR), real-time PCR, transcription-mediated amplification (TMA), rolling circle amplification, nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), Transcription-Mediated Amplification (TMA), Single Primer Isothermal Amplification (SPIA), Helicase-dependent amplification (HDA), Loop mediated amplification (LAMP), Recombinase-Polymerase Amplification (RPA), and ligase chain reaction (LCR).
  • PCR polymerase chain reaction
  • RT-PCR reverse-transcriptase PCR
  • TMA transcription-mediated amplification
  • NASBA nucleic acid sequence-based amplification
  • SDA strand displacement a
  • amplification of CMV or EBV nucleic acid sequences is performed using isothermal amplification(e. ., RPA or NEAR). In some embodiments, amplification and detection of CMV or EBV nucleic acid sequences is performed using a point of care device (e.g., the ID NOW system (Abbott)).
  • a point of care device e.g., the ID NOW system (Abbott)
  • amplification of CMV or EBV nucleic acid sequences is performed using real-time PCR.
  • “Real-time PCR,” as used herein, refers to a PCR method in which the accumulation of amplification product is measured as the reaction progresses, in real time, with product quantification after each cycle, in contrast to conventional PCR in which the amplified DNA product is detected in an end-point analysis.
  • Real-time PCR also is known in the art as “quantitative PCR (qPCR).”
  • Real-time detection of PCR products typically involves the use of non-specific fluorescent dyes that intercalate with any doublestranded DNA and sequence-specific fluorescently-labeled DNA probes.
  • Real-time PCR techniques and systems are known in the art (see, e.g., Dorak, M. Tevfik, ed. Real-time PCR. Taylor & Francis (2007); and Fraga et al., “Real-time PCR,” Current protocols essential laboratory techniques'.
  • the isothermal amplification methods may rely on nicking and extension reactions, “nicking and extension amplification,” to amplify shorter sequences in a quicker timeframe than traditional amplification reactions.
  • nicking and extension amplification may include, for example, reactions that use only two amplification oligonucleotides, one or two nicking enzymes, and a polymerase, under isothermal conditions.
  • a target nucleic acid sequence having a sense and antisense strand
  • a pair of amplification oligonucleotides is contacted with a pair of amplification oligonucleotides.
  • the first amplification oligonucleotide comprises a nucleic acid sequence comprising a recognition region at the 3' end that is complementary to the 3' end of the target sequence antisense strand, a nicking enzyme site upstream of said recognition region, and a stabilizing region upstream of said nicking enzyme site.
  • the second amplification oligonucleotide comprises a nucleotide sequence comprising a recognition region at the 3' end that is complementary to the 3' end of the target sequence sense strand, a nicking enzyme site upstream of said recognition region, and a stabilizing region upstream of said nicking enzyme site.
  • Two nicking enzymes are provided.
  • One nicking enzyme is capable of nicking at the nicking enzyme site of the first amplification oligonucleotide but incapable of nicking within said target sequence.
  • the other nicking enzyme is capable of nicking at the nicking enzyme site of the second amplification oligonucleotide but incapable of nicking within said target sequence.
  • a DNA polymerase is employed under conditions for amplification which involves multiple cycles of extension of the amplification oligonucleotides thereby producing a double-stranded nicking enzyme site which are nicked by the nicking enzymes to produce the amplification product.
  • a DNA polymerase is employed under conditions for amplification which involves multiple cycles of extension of the amplification oligonucleotides thereby producing a double-stranded nicking enzyme site which are nicked by the nicking enzymes to produce the amplification product.
  • amplification of CMV or EBV nucleic acid sequences is performed using Recombinase-Polymerase Amplification (RPA), which relies on the properties of recombinases and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions.
  • RPA Recombinase-Polymerase Amplification
  • a recombinase agent is contacted with first and second amplification oligonucleotides to form nucleoproteins.
  • nucleoproteins contact the target sequence to form a first double stranded structure at a first portion of said first strand and form a double stranded structure at a second portion of said second strand so the 3' ends of said first amplification oligonucleotide and the second amplification oligonucleotide are oriented towards each other on the DNA comprising the target sequence.
  • the 3' end of the amplification oligonucleotides in the nucleoprotein are extended by DNA polymerases to generate first and second double stranded nucleic acids, and first and second displaced strands of nucleic acid. The steps are repeated until the desired level of amplification is achieved.
  • suitable recombinase agents include the A’, coli RecA protein, the T4 uvsX protein, or any homologous protein or protein complex from any phyla.
  • Other non-homologous recombinase agents may be utilized in place of RecA, for example as RecT, or RecO.
  • Suitable recombinase loading proteins may include, for example, T4uvsY, E. coli recO, E. coli recR and derivatives and combinations of these proteins.
  • Suitable single stranded DNA binding proteins may be the E. coli SSB or the T4 gp32 or a derivative or a combination of these proteins.
  • the DNA polymerase may be a eukaryotic or prokaryotic polymerase.
  • Examples of eukaryotic polymerases include pol-a, pol-P, pol-8, pol-s and derivatives and combinations thereof.
  • Examples of prokaryotic polymerase include E. coli DNA polymerase I Klenow fragment, bacteriophage T4 gp43 DNA polymerase, Bacillus stearothermophilus polymerase I large fragment, Phi-29 DNA polymerase, T7 DNA polymerase, Bacillus subtilis Pol I, E. coli DNA polymerase I, E. coli DNA polymerase II, E. coli DNA polymerase III, E. coli DNA polymerase IV, E. coli DNA polymerase V and derivatives and combinations thereof.
  • RPA Reactive protein kinase
  • ATP ATP
  • ATP analog ATP
  • ATP-P-S ATP-P-S
  • ddATP phosphate
  • the RPA reaction may also include a system to regenerate ADP from AMP and a to convert pyrophosphate to phosphate (pyrophosphate).
  • Suitable crowding agents used in RPA include polyethylene glycol (PEG), dextran and ficoll.
  • the disclosed method may further comprise hybridizing one or more of the probe oligonucleotide sequences disclosed herein to the one or more amplified target CMV or EBV nucleic acid sequences.
  • the method comprises detecting hybridization of the one or more probe oligonucleotide sequences to the one or more amplified target nucleic acid sequences by assessing a signal from each of the detectable labels, whereby (i) the presence of one or more signals indicates hybridization of the one or more probe oligonucleotide sequences to the one or more target CMV or EBV nucleic acid sequences and the presence of CMV or EBV in the sample, and (ii) the absence of signals indicates the absence of CMV or EBV in the sample.
  • Detection of signals from the one or more probe oligonucleotide sequences may be performed using a variety of well-known methodologies, depending on the type of detectable label. For example, detection may be done using solution real-time fluorescence or using a solid surface method.
  • the present invention provides compositions, methods, systems and kits for multiplex isolation, detection, identification and/or quantification of CMV and EBV in whole blood wherein CMV and EBV are simultaneously isolated, detected, identified and/or quantified in a single sample and/or reaction vessel.
  • a subject identified according to the methods described herein as having CMV or EBV may be treated, monitored (e.g., for the presence of a CMV or EBV nucleic acid determined in a sample from the subject), treated and monitored, and/or monitored and treated using routine techniques known in the art.
  • the methods described herein further include treating the subject when the presence of CMV or EBV nucleic acid is determined in one or more samples obtained from the subject using the present methods. Kits
  • the disclosure also provides a kit for amplifying and detecting CMV or EBV in a sample.
  • the kit comprises at least one oligonucleotide as described herein.
  • the kit comprises a set or group of oligonucleotides described herein.
  • the kit may further comprise reagents for amplifying and detecting nucleic acid sequences, and instructions for amplifying and detecting CMV or EBV. Descriptions of the oligonucleotides and sets of oligonucleotides set forth herein with respect to the aforementioned methods also are applicable to those same aspects of the kit described herein. Many such reagents are described herein or otherwise known in the art and commercially available.
  • suitable reagents for inclusion in the kit include conventional reagents employed in nucleic acid amplification reactions, such as, for example, one or more enzymes having polymerase activity, enzyme cofactors (such as magnesium or nicotinamide adenine dinucleotide (NAD)), salts, buffers, deoxyribonucleotide, or ribonucleotide triphosphates (dNTPs/rNTPs; for example, deoxyadenosine triphosphate, deoxyguanosine triphosphate, deoxycytidine triphosphate, and deoxythymidine triphosphate) blocking agents, labeling agents, and the like.
  • enzyme cofactors such as magnesium or nicotinamide adenine dinucleotide (NAD)
  • NAD nicotinamide adenine dinucleotide
  • salts such as magnesium or nicotinamide adenine dinucleotide (NAD)
  • NAD nic
  • kits of the present invention comprise one or more of a calibrator, a positive control, a negative control and/or an internal control.
  • the kit may comprise instructions for using the amplification reagents and oligonucleotides described herein, e.g., for processing the test sample, extracting nucleic acid molecules, and/or performing the test; and for interpreting the results obtained.
  • the instructions may be printed or provided electronically (e.g., DVD, CD, or available for viewing or acquiring via internet resources).
  • the kit may be supplied in a solid (e.g., lyophilized) or liquid form.
  • the various components of the kit of the present disclosure may optionally be contained within different containers (e.g., vial, ampoule, test tube, flask, or bottle) for each individual component (e.g., amplification oligonucleotides, probe oligonucleotides, or buffer).
  • Each component will generally be suitable as aliquoted in its respective container or provided in a concentrated form.
  • Other containers suitable for conducting certain steps of the amplification/detection assay may also be provided.
  • the individual containers are preferably maintained in close confinement for commercial sale.
  • the kit may further comprise a swab for obtaining a biological sample.
  • the kit comprises reagents for gaining access to and/or extracting/isolating nucleic acid from a biological sample.
  • the present invention provides systems for amplifying and detecting CMV or EBV in a sample.
  • the system performs sample preparation, amplification and detection of target nucleic acid sequences using, for example, real-time PCR.
  • a system operator interacts with a touch screen to select icons, buttons, menu commands, and other screen elements.
  • a monitor displays a user interface of the system and accepts on-screen /touchscreen selections from the operator.
  • optional components include a keyboard, a pointing mouse, system information, software function and updates and online help.
  • the two or more sample preparation steps of the system are executed automatically.
  • the system comprises sample preparation protocols that are shared between plasma and urine specimens.
  • systems of the present invention perform continuous and random-access sample processing using multiple sample processors and thermocyclers in parallel.
  • an individual sample occupies a single sample lane followed by an associated PCR amplification-detection lane.
  • parallel lanes provide access to 300 or more samples per day in 2-8 hours from first aspiration to test result.
  • the system’s capacity incorporates all required reagents in integrated reaction units (IRUs). Samples and controls for a walk away time of 2-4 hours with continuous operator access to remove or replenish amplification reagents, ancillary reagents and commodities without interfering with system processing.
  • the system comprises a plurality of Assay Processing Units configured for sample preparation and amplification-detection.
  • the system provides individual fluorescent dye intensity changes over PCR cycles.
  • data reduction comprises a maxRatio algorithm.
  • the maxRatio algorithm evaluates 2 features of assay results: 1) When the Reduced Fluorescence Intensity curves crosses a threshold, the algorithm determines whether a signal corresponds to PCR amplification of the true target’s existence (i.e., whether the PCR is reactive) based on maxRatio’s “peak PCR efficiency” analysis; 2) For rising signals, the algorithm determines whether there is an interference to the PCR (e.g., inhibition of noise) that potentially affects the accuracy of the assay result based on the maxRatio’s “curve shape” analysis.
  • an interference to the PCR e.g., inhibition of noise
  • cycle number (CN) corresponding to the peak maxRatio value (MR) is identified as the Fractional Cycle Number (FCN).
  • Cycle threshold (CT) and FCN are inversely proportional to the Log of the target concentration in the sample prior to amplification. The algorithm provides an additional confirmation of the data’s quality and provides confidence for the reported results.
  • systems and kits of the present invention comprise positive controls, negative controls, internal controls (for example, rehydrated from a lypholized unit dose), and calibrators.
  • systems, kits and methods comprise reagents and components configured to remove PCR inhibitors from sample DNA extract.
  • the PCJR Mastermix reagent formulation is compatible with lyophilization and enables fast PCR (completion of cycling in less than one hour).
  • Mastrermix Reagent was prepared by combining KAPA 2G DNA Polymerase, MT9 complex excipient, and CMV oligonucleotide mix (consisting of molecular biology grade water, PCR buffer components, dNTPs, oligonucleotide primers and probes, and Cal Fluor Red 610 passive reference dye).
  • the Mastermix reagent formulation is shown in Table 3.
  • KAPA2G Polymerase is an engineered enzyme for higher processivity and speed through directed evolution. It provides significantly faster extension rates than wild-type Taq DNA polymerase. It has a highly processive 5’-3’ DNA polymerase but lacking 3 ’-5’ exonuclease activity.
  • Activator solution was prepared by mixing molecular biology grade water, ProCiin 950, magnesium chloride, potassium chloride and tetramethyl ammonium chloride (TMAC).
  • TMAC tetramethyl ammonium chloride
  • the activator solution provides the reaction with the necessary salts to activate PCR enzymes and establish an ionic strength environment that is conducive to efficient amplification.
  • the Activator Reagent Formulation is shown in Table 4.
  • the internal control contains the pumpkin hydroxypyruvate reductase cDNA sequences, which is unrelated to CMV target sequences.
  • Internal Control / Proteinase K Reagent is prepared by mixing trehalose with water, 2X Internal Control Bulk (consisting of Internal Control plasmid DNA and Tris-based buffer containing salmon testes DNA), Proteinase K and an IC Diluent (consisting of Tris-based buffer containing salmon testes DNA). The formulation of the internal control is shown in Table 5.
  • magnetic microparticles with bound sample DNA were captured by a magnetic plunger sheathed with a disposable plastic sleeve.
  • the magnetic microparticles were then successively transferred to wells within the IRU containing a series of wash solutions with ethanol.
  • wash steps were complete, the magnetic silica microparticles were captured by the plunger magnet and transferred into an elution well within the IRU where the purified DNA is eluted from the microparticles into Alinity m Elution Buffer 1.
  • the purified DNA eluate and unit-dose Alinity m EBV WB real-time PCR reagents were combined by the Alinity m System and transferred to a real-time PCR reaction vessel (RV).
  • a layer of Alinity m Vapor Barrier Solution was then automatically added to the RV.
  • the RV was then capped and transferred to a thermal cycling position on the APU for amplification/detection.
  • PCR Mastermix reagent formulation is compatible with lyophilization and enables fast PCR (completion of cycling in less than one hour).
  • Mastermix reagent was prepared by combining KAPA 2G DNA Polymerase, MT9 complex excipient, and EBV oligonucleotide mix (consisting of molecular biology grade water, PCR buffer components, dNTPs, oligonucleotide primers and probes, and Cal Fluor Red 610 passive reference dye).
  • the formulation of the Mastermix Reagent is shown in Table 10.
  • Table 10 PCR EBV Mastermix reagent formulation *KAPA2G Polymerase is an engineered enzyme for higher processivity and speed through directed evolution. It offers significantly faster extension rates than wild-type Taq DNA polymerase. It has a highly processive 5’-3’ DNA polymerase but lacking 3 ’-5’ exonuclease activity.
  • Activation Reagent was prepared by mixing molecular biology grade water, ProCiin 950, magnesium chloride, potassium chloride and tetramethyl ammonium chloride (TMAC).
  • the activator solution provides reaction with the necessary salts to activate PCR enzymes and establish an ionic strength environment that is conducive to efficient amplification.
  • the formulation of the Activator Reagent Formulation is shown in Table 11.
  • the EBV Internal Control / Proteinase K Reagent is prepared by mixing trehalose with water, 2X Internal Control Bulk (consisting of Internal Control plasmid DNA and Tris-based buffer containing salmon testes DNA), Proteinase K and an IC Diluent (consisting of Trisbased buffer containing salmon testes DNA).
  • the Internal Control Formulation is shown in Table 12.
  • PCR cycling conditions used by the Alinity m EBV assay are shown in Table 13. Table 13. PCR cycling conditions
  • Alinity m Lysis Solution inactivates the Proteinase K, lyses cells and denatures proteins in the sample, and promotes nucleic acid binding to the magnetic microparticles during the lysis incubation step.
  • magnetic microparticles with bound sample DNA were captured by a magnetic plunger sheathed with a disposable plastic sleeve. The magnetic microparticles were then successively transferred to wells within the IRU containing a series of wash solutions with ethanol. After the wash steps were complete, the magnetic silica microparticles were captured by the plunger magnet and transferred into an elution well within the IRU where the purified DNA was eluted from the microparticles into Alinity m Elution Buffer 1.
  • the purified DNA eluate and unit-dose Alinity m EBV WB real-time PCR reagents were combined by the Alinity m System and transferred to a real-time PCR reaction vessel (RV).
  • a layer of Alinity m Vapor Barrier Solution was then automatically added to the RV.
  • the RV was then capped and transferred to a thermal cycling position on the APU for amplification/detection.
  • Fresh whole blood samples were collected from 5 control healthy donors to test pretreatment with and without GITC pretreatment. 200uL of GITC was added to the pretreatment well (final GITC concentration 1.88M). Samples were tested with and without 0.8U and 1.2U of PK. 300uL of whole blood sample was aspirated in each case. Whole blood samples were also tested on m2000 EBV WB assay for comparison. Samples were not spiked with exogenous EBV virus or DNA to test detection of endogenous donor EBV as a more challenging target than spiked material.
  • Table 16 shows the number of detected/valid replicates for 5 normal donors tested on the m2000 platform compared to 4 different sample preparation conditions on the Alinity mEBV whole blood (WB) platform.
  • Condition 3 comprising GITC pretreatment with 0.8U PK had the highest detection on Alinity and matched m2000 detection. This detection was significantly higher than pretreatment with no PK. Higher PK levels had a similar if lower level of detection, but also had 2 fluorescence errors which could indicate that there were contaminants in the eluate (e.g., microparticle carryover, and/or whole blood proteins). Extraction without pretreatment, or preteatment with no PK, had lower overall detection of EBV.
  • Example 4 Pretreatment GITC concentration
  • Table 17 Conditions tested Table 18. shows the mean and standard deviation (SD) for Target FAM and IC Q670 Ct and MR for each condition tested. Increasing GITC concentration in pretreatment trended to early FAM Cts. The highest GITC level tested had increased SD indicating inconsistent target recovery. Addition of 0.4U of PK further decreased sample variability at 2.69M GITC and also has earlier IC Ct.
  • SD standard deviation
  • Table 19 shows the target FAM and IC Q670 Ct for each condition tested.
  • FAM target increasing GITC concentration in pretreatment trended to early FAM Cts, but increased variability at higher levels.
  • For IC increasing GITC levels also lead to earlier Cts up to 2.69M.
  • the addition of PK further decreased the IC Ct.
  • Table 20 Pretreatment conditions Addition of PEG did not improve target recovery.
  • Table 21. Addition of SDS in pretreatment did not improve target recovery and further increased error rates.
  • Table 21. Error rates decreased when the ratio of sample to lysis volume in pretreatment decreased.
  • Table 22. Addition of PK improved target recovery.
  • Table 21. Table 21. 1E3 lU/mL EBV inactivated virus panel test results

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés, des compositions, des kits et des systèmes pour détecter des séquences d'acides nucléiques cibles à partir du cytomégalovirus (CMV) ou du virus d'Epstein-Bar (EBV).
PCT/US2024/044002 2023-08-28 2024-08-27 Dosages pour détecter le cytomégalovirus (cmv) ou le virus d'epstein-bar (ebv) Pending WO2025049451A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363534934P 2023-08-28 2023-08-28
US63/534,934 2023-08-28
US202463564277P 2024-03-12 2024-03-12
US63/564,277 2024-03-12

Publications (1)

Publication Number Publication Date
WO2025049451A1 true WO2025049451A1 (fr) 2025-03-06

Family

ID=92800504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/044002 Pending WO2025049451A1 (fr) 2023-08-28 2024-08-27 Dosages pour détecter le cytomégalovirus (cmv) ou le virus d'epstein-bar (ebv)

Country Status (1)

Country Link
WO (1) WO2025049451A1 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270981B2 (en) 2002-02-21 2007-09-18 Asm Scientific, Inc. Recombinase polymerase amplification
US7399590B2 (en) 2002-02-21 2008-07-15 Asm Scientific, Inc. Recombinase polymerase amplification
US8030000B2 (en) 2002-02-21 2011-10-04 Alere San Diego, Inc. Recombinase polymerase amplification
US8071308B2 (en) 2006-05-04 2011-12-06 Alere San Diego, Inc. Recombinase polymerase amplification
US9096897B2 (en) 2012-04-09 2015-08-04 Envirologix Inc. Compositions and methods for quantifying a nucleic acid sequence in a sample comprising a primer oligonucleotide with a 3′-terminal region comprising a 2′-modified nucleotide
US9562264B2 (en) 2007-07-14 2017-02-07 Ionian Technologies, Inc. Nicking and extension amplification reaction for the exponential amplification of nucleic acids
WO2018063772A1 (fr) * 2016-09-27 2018-04-05 Abbott Molecular Inc. Maximisation du rendement en adn d'échantillons de sang prélevés dans des tubes à caillot rapide
CN114457069A (zh) * 2022-03-07 2022-05-10 江苏迅睿生物技术有限公司 一种磁珠法病原体核酸提取试剂盒及使用方法
WO2022232601A1 (fr) * 2021-04-29 2022-11-03 Abbott Laboratories Test d'acides nucléiques à haut débit d'échantillons biologiques
CN116179535A (zh) * 2022-12-21 2023-05-30 西安天隆科技有限公司 一种快速核酸提取或纯化试剂盒

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10329602B2 (en) 2002-02-21 2019-06-25 Alere San Diego, Inc. Recombinase polymerase amplification
US10036057B2 (en) 2002-02-21 2018-07-31 Alere San Diego, Inc. Recombinase polymerase amplification
US7666598B2 (en) 2002-02-21 2010-02-23 Twistdx, Inc. Recombinase polymerase amplification
US8017339B2 (en) 2002-02-21 2011-09-13 Alere San Diego, Inc. Compositions and kits for recombinase polymerase amplification
US8030000B2 (en) 2002-02-21 2011-10-04 Alere San Diego, Inc. Recombinase polymerase amplification
US10947584B2 (en) 2002-02-21 2021-03-16 Abbott Diagnostics Scarborough, Inc. Recombinase polymerase amplification
US8426134B2 (en) 2002-02-21 2013-04-23 Alere San Diego, Inc. Recombinase polymerase amplification
US8460875B2 (en) 2002-02-21 2013-06-11 Alere San Diego, Inc. Recombinase polymerase amplification
US8574846B2 (en) 2002-02-21 2013-11-05 Alere San Diego, Inc. Recombinase polymerase amplification
US10329603B2 (en) 2002-02-21 2019-06-25 Alere San Diego Inc. Recombinase polymerase amplification
US8945845B2 (en) 2002-02-21 2015-02-03 Alere San Diego Inc. Recombinase polymerase amplification
US8962255B2 (en) 2002-02-21 2015-02-24 Alere San Diego, Inc. Recombinase polymerase amplification
US7270981B2 (en) 2002-02-21 2007-09-18 Asm Scientific, Inc. Recombinase polymerase amplification
US9663820B2 (en) 2002-02-21 2017-05-30 Alere San Diego Inc. Recombinase polymerase amplification
US7399590B2 (en) 2002-02-21 2008-07-15 Asm Scientific, Inc. Recombinase polymerase amplification
US8637253B2 (en) 2006-05-04 2014-01-28 Alere San Diego, Inc. Recombinase polymerase amplification
US11339382B2 (en) 2006-05-04 2022-05-24 Abbott Diagnostics Scarborough, Inc. Recombinase polymerase amplification
US8071308B2 (en) 2006-05-04 2011-12-06 Alere San Diego, Inc. Recombinase polymerase amplification
US10093908B2 (en) 2006-05-04 2018-10-09 Alere San Diego, Inc. Recombinase polymerase amplification
US9562263B2 (en) 2007-07-14 2017-02-07 Ionian Technologies, Inc. Nicking and extension amplification reaction for the exponential amplification of nucleic acids
US9689031B2 (en) 2007-07-14 2017-06-27 Ionian Technologies, Inc. Nicking and extension amplification reaction for the exponential amplification of nucleic acids
US9617586B2 (en) 2007-07-14 2017-04-11 Ionian Technologies, Inc. Nicking and extension amplification reaction for the exponential amplification of nucleic acids
US9562264B2 (en) 2007-07-14 2017-02-07 Ionian Technologies, Inc. Nicking and extension amplification reaction for the exponential amplification of nucleic acids
US10851406B2 (en) 2007-07-14 2020-12-01 Ionian Technologies, Llc Nicking and extension amplification reaction for the exponential amplification of nucleic acids
US9096897B2 (en) 2012-04-09 2015-08-04 Envirologix Inc. Compositions and methods for quantifying a nucleic acid sequence in a sample comprising a primer oligonucleotide with a 3′-terminal region comprising a 2′-modified nucleotide
WO2018063772A1 (fr) * 2016-09-27 2018-04-05 Abbott Molecular Inc. Maximisation du rendement en adn d'échantillons de sang prélevés dans des tubes à caillot rapide
WO2022232601A1 (fr) * 2021-04-29 2022-11-03 Abbott Laboratories Test d'acides nucléiques à haut débit d'échantillons biologiques
CN114457069A (zh) * 2022-03-07 2022-05-10 江苏迅睿生物技术有限公司 一种磁珠法病原体核酸提取试剂盒及使用方法
CN116179535A (zh) * 2022-12-21 2023-05-30 西安天隆科技有限公司 一种快速核酸提取或纯化试剂盒

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
"PCR Protocols. A Guide to Methods and Applications,", 1990, ACADEMIC PRESS
"PCR Strategies", 1995, ACADEMIC PRESS
A. H. HOPMAN ET AL., EXP. CELL RES., vol. 169, 1987, pages 357 - 368
ALTSCHUL ET AL., J. MOLECULAR BIOL., vol. 215, no. 3, 1990, pages 403 - 410
BAYER ET AL., METHODS OF BIOCHEM. ANALYSIS, vol. 26, 1980, pages 1 - 45
BEIGERT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 106, no. 10, 2009, pages 3770 - 3775
BELOUSOV ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3440 - 3444
BRIGATI ET AL., VIROL, vol. 126, 1983, pages 32 - 50
BROKER ET AL., NUCL. ACIDS RES., vol. 5, 1978, pages 363 - 384
CONNOLY ET AL., NUCL. ACIDS. RES., vol. 13, 1985, pages 4485 - 4502
DURBIN ET AL.: "Biological Sequence Analysis: Probalistic Models of Proteins and Nucleic Acids", 2009, CAMBRIDGE UNIVERSITY PRESS
FRAGA ET AL.: "Real-time PCR", CURRENT PROTOCOLS ESSENTIAL LABORATORY TECHNIQUES:, 2008, pages 10 - 3
GIJLSWIJK ET AL., EXPERT REV. MOL. DIAGN.,, vol. 1, 2001, pages 81 - 91
GUSFIELD: "Algorithms on Strings,", 1997, CAMBRIDGE UNIVERSITY PRESS
JOOS ET AL., J. BIOTECHNOL., vol. 35, 1994, pages 135 - 153
L. J. KRICKA, ANN. CLIN. BIOCHEM., vol. 39, 2002, pages 114 - 129
LANDEGENT ET AL., EXP. CELL RES., vol. 15, 1984, pages 61 - 72
LANGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 6633 - 6637
MAXAM ET AL., METHODS OF ENZYMOLOGY, vol. 65, 1980, pages 499 - 560
MCFARLAND ET AL., NUCLEIC ACIDS RES., vol. 7, 1979, pages 1067 - 1080
NARANG ET AL., METH. ENZYMOL., vol. 68, 1979, pages 109 - 151
PEARSON ET AL., J. CHROM., vol. 255, 1983, pages 137 - 149
PIELES ET AL., NUCLEIC ACIDS RES., vol. 21, 1993, pages 3191 - 3196
RICHARDSON ET AL., NUCL. ACIDS RES., vol. 11, 1983, pages 6167 - 6184
SAMBROOK ET AL.: "Molecular Cloning. A Laboratory Manual,", 1989, COLD SPRING HARBOUR LABORATORY PRESS: NEW YORK
SMITH ET AL., NUCL. ACIDS RES., vol. 13, 1985, pages 2399 - 2412
SODING, BIOINFORMATICS, vol. 21, no. 7, 2005, pages 951 - 960
TAYLORFRANCIS: "Real-time PCR", 2007
TCHEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 3466 - 3470
TEMSAMANI ET AL., MOL. BIOTECHNOL., vol. 5, 1996, pages 223 - 232
WU ET AL., ANAL. BIOCHEM., vol. 290, 2001, pages 347 - 352

Similar Documents

Publication Publication Date Title
EP2528932B1 (fr) Procédés et compositions pour la purification et l'analyse multiplexée d'acides nucléiques séquence-spécifique
US8623602B2 (en) Lysis and reverse transcription for MRNA quantification
EP3241915A1 (fr) Compositions et procédé pour la détection du virus du nil occidental
JP2009545317A (ja) 分析物および核酸の検出
US12018328B2 (en) Assay for detecting human papilloma virus (HPV)
EP4022086B1 (fr) Compositions et procédés pour l'amplification et la détection de l'arn du virus de l'hépatite b, comprenant l'arn du vhb transcrit à partir de adnccc
EP3628059B1 (fr) Dosage pour la détection du virus de l'immunodéficience humaine (vih)
JP2022501073A (ja) 水痘帯状疱疹ウイルスを増幅または検出するための組成物および方法
US11028439B2 (en) Assay for detecting hepatitis B virus (HBV)
EP3628060B1 (fr) Dosage pour la détection du virus de l'hépatite c (vhc)
WO2025049451A1 (fr) Dosages pour détecter le cytomégalovirus (cmv) ou le virus d'epstein-bar (ebv)
EP2625285B1 (fr) Méthode de lyse cellulaire et pcr à l'intérieur du même récipient de réaction
WO2025049450A1 (fr) Dosages pour détecter un virus bk (bkv)
US20230313323A1 (en) Assays for detecting coronavirus disease 2019 (covid-19)
WO2024030985A1 (fr) Dosages pour la détection virale de la variole du singe
HK1220496A1 (en) Assay for detecting and quantifying hiv-1
GB2559919A (en) Method of isolating nucleic acid from specimens in liquid-based cytology preservatives containing formaldehyde

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24772485

Country of ref document: EP

Kind code of ref document: A1